论文部分内容阅读
2012年9月,美国FDA批准了Novartis公司提交的更高剂量卡巴拉汀(rivastigmine)透皮贴膏Exelon13.3mg/24h的补充新药申请,用于一日1剂贴敷治疗已见总功能和认知下降的轻至中度阿尔茨海默病患者。Exelon是迄今在美获准治疗阿尔茨海默病的唯一一种透皮贴膏,原获准剂量规格有4.6mg/24h和9.5mg/24h两种。Exelon先前也已在美获准治疗帕金森病相关轻至中度痴呆。
In September 2012, the U.S. FDA approved Novartis’ application for a new dose of a higher-dose rivastigmine transdermal patch of Exelon at 13.3 mg / 24 hours for one day of patch application as seen on the total function and Cognitive decline in patients with mild to moderate Alzheimer’s disease. Exelon is the only transdermal patch in the US approved for the treatment of Alzheimer’s disease. The original approved dosage is 4.6mg / 24h and 9.5mg / 24h. Exelon has also previously been approved for the treatment of Parkinson’s disease-associated mild to moderate dementia in the United States.